BOSTON (TheStreet) -- Adam Feuerstein's take on the biotech week that was Oct. 11, 2010:
Pfizer (PFE) buys King Pharmaceuticals (KG) for $3.6 billion to bolster its pain drug franchise.
Pfizer adds new partners through King Buy
Alkermes (ALKS) CEO Richard Pops (@popsalks) breaks company news on Twitter. Bravo! (via @MikeHuckman)
The news broken by Pops: Finally, a drug approval in October! Alkermes received FDA clearance to market Vivitrol as a treatment for opioid addiction
Alexza Pharmaceuticals (ALXA)
and Jazz Pharmaceuticals (JAZZ)
not as lucky: FDA denies approval to both of their drugs
Questcor Pharmaceuticals (QCOR)
receives belated FDA approval for Acthar as a treatment for infantile spasms.
The week's top-performing sector stocks: Pharmathene (PIP)
(+120%), Molecular Insight Pharmaceuticals (MIPI)
(+65%), Rosetta Genomics (ROSG)
(+60%), SIGA Technologies (SIGA)
(+56%) and King Pharmaceuticals (KG)
Johnson & Johnson's (JNJ) abiraterone boosts survival by four months
for patients with advanced prostate cancer.
Seattle Genetics (SGEN)
reported a second clinical trial win for the lymphoma drug brentuximab vedotin.
This week's Biotech Stock Mailbag
: Exact Sciences (EXAS)
, Sequenom (SQNM)
, Vanda Pharmaceuticals (VNDA)
, Delcath Systems (DCTH)
, Labopharm (DDSS)
, Cadence Pharmaceuticals (CADX)
and Transcept Pharmaceuticals (TSPT)
Matt Herper on the fight against drug-resistant germs
Cancer drug analyst and blogger Sally Church spends the week at the European cancer conference known as ESMO
The week's worst-performing sector stocks: Alexza Pharmaceuticals (ALXA)
(-56%), Spherix (SPEX)
(-24%), AspenBio Pharma (APPY)
(-17%), Anadys Pharmaceuticals (ANDS)
(-16%) and ProPhase Labs (PRPH)
Cubist Pharmaceuticals (CBST)
reports third quarter Cubicin sales of $154 million, lower than the consensus estimate of $162 million. The company reports higher-than-expected earnings for the quarter on lower operating expenses.
The biggest (sore) losers: Arena Pharmaceuticals (ARNA) investors
Chemist and blogger Derek Lowe takes another skeptical look at the anti-aging claims
made about GlaxoSmithKline's resveratrol.
Will the withdrawal of Meridia help or hurt other weight-loss pills
? (via Pharmalot)
editor Ivan Oransky on Geron (GERN)
and its first-ever stem cell study in patients with spinal cord injury
"Scrapers" are scouring web sites looking for patients' personal information
reports weaker-than-expected sales of its three most important drugs -- Avastin, Rituxan and Herceptin. Overall, third quarter revenue fell 7%.
and Novartis (NVS)
strike a licensing deal to develop cancer drugs based on ImmunoGen's "armed antibody" drug delivery technology.
licenses two experimental cancer drugs to Bristol-Myers Squibb (BMY)
Perfect FDA Drug Approval Pickers
Halozyme Therapeutics (HALO)
cut 25% of its workforce in a restructuring move.
The week in financings: Regeneron Pharmaceuticals (RGEN)
($175 million), Cytori Therapeutics (CYTX)
($19 million) and Anadys Pharmaceuticals (ANDS)
FDA doesn't always heed the recommendations offered by its advisory panels
. (via @matthewherper)
Phase III data on Titan Pharmaceuticals' (TTNP.OB) implantable addiction drug is published in JAMA
Boehringer Ingelheim drops development of a drug for the controversial disorder known as female sexual dysfunction
completes acquisition of Abraxis BioScience
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein
>To submit a news tip, send an email to: email@example.com